Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need November 24, 2025
FDA aligned on the design of pivotal study of pelareorep + SOC for 1L treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) November 24, 2025
NDA accepted; PDUFA Date announced for n.c.a. 177Lu-edotreotide (ITM-11) in GEP-NETs November 18, 2025
MHRA Approves CTA for YntraDose™ in unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC) November 18, 2025
Robust T cell Responses Reported Across Diverse HLA backgrounds in Ph 2 AMPLIFY-7P Trial of ELI-002 October 29, 2025
Positive Data from Ongoing Ph 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers Reported October 29, 2025
First patients enrolled in Ph 1 trial with KQB548 (BAY 3771249) in KRAS G12D-mutated tumors October 21, 2025
FAILED TRIAL: Zolbetuximab Ph 2 GLEAM Trial Did Not Meet Primary Endpoint of OS in Patients with Metastatic Pancreatic Cancer October 15, 2025
OPTIMIZE-1 biomarker analysis published in Cell Reports Medicine supporting mitazalimab and mFOLFIRINOX in metastatic pancreatic cancer October 15, 2025
AlphaMedix™ (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in Ph 2 study in patients with GEP-NETs October 15, 2025
Dosimetry Data from Ph 3 COMPETE Trial Supports Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with GEP-NETs October 15, 2025
Alignment with FDA obtained on study design to advance two Ph 3 trials in gastroesophageal cancers (FAPI-GO) and PDAC (FAPI-PRO), with [18F] FAPI-74 October 7, 2025
Encouraging Preliminary Results from the Pancreatic Cancer Cohort of Ph 1/2a CENDIFOX Trial of certepetide + chemo combo Announced September 30, 2025
Investigator-Initiated Ph 1 Trial for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma planned September 30, 2025
86% OS at 9 Months observed in 1L Pancreatic Cancer Patients Treated with Atebimetinib + mGnP September 30, 2025
FDA Granted Orphan Drug Designation to Utidelone for the Treatment of Pancreatic Cancer September 30, 2025
ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable pancreatic cancer patients in Ph 2 AMPLIFY-7P Trial September 23, 2025
IND application amended with updated OS data from Ph 2 Actuate-1801 Part 3B trial of elraglusib + GnP versus GnP alone in 1L metastatic pancreatic cancer September 23, 2025
First Patient Dosed in Ph 2 Study of AK130 + Ivonescimab for Advanced Pancreatic Cancer September 23, 2025
Final results from OPTIMIZE-1 trial of mitazalimab – mFOLFIRINOX combo in 1L metastatic pancreatic cancer patients announced September 23, 2025
New Data Supports Initiation of Ph 3 RASolute 303 Registrational Trial of Daraxonrasib in 1L Metastatic Pancreatic Ductal Adenocarcinoma September 16, 2025
Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology September 16, 2025
Premarket approval (PMA) application submitted to FDA for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer August 26, 2025
